Document Detail

A meta-analysis of randomized trials on clinical outcomes of paclitaxel-eluting stents versus bare-metal stents in ST-segment elevation myocardial infarction patients.
MedLine Citation:
PMID:  20872982     Owner:  NLM     Status:  MEDLINE    
A meta-analysis was performed to address the efficacy and safety of paclitaxel-eluting stent (PES) in ST-segment elevation myocardial infarction (STEMI) patients. A systematic literature search was conducted to identify all randomized clinical trials in mortality, recurrent myocardial infarction (rMI), repeat revascularization (RR), and stent thrombosis (ST). A total of 4190 STEMI patients were enrolled in six randomized trials comparing PES with bare-metal stent (BMS). The pooled repeat revascularization rate was 5.7% in PES group, significantly lower than 10.0% in BMS group with an odds ratio (OR) of 0.56, 95% confidence interval (CI) [0.44, 0.72] (P<0.00001). No significant difference was found between PES and BMS groups in mortality at one year after the indexing procedure (3.9% vs. 5.1%, OR 0.88, 95% CI [0.63, 1.21], P=0.42). Similarly, rMI rate did not differ significantly between the two groups (3.4% vs. 4.1%, OR 0.80, 95% CI [0.56, 1.13], P=0.21). PES was also associated with the comparable pooled rate of definite stent thrombosis with BMS (2.3% vs. 2.4%, OR 0.81, 95% CI [0.52, 1.26], P=0.35). The results show that PES improved clinical outcomes in STEMI patients with a decreased need for repeat revascularization and no concerns for safety.
Xiao-hong Pan; Ying-xue Chen; Mei-xiang Xiang; Geng Xu; Jian-an Wang
Publication Detail:
Type:  Journal Article; Meta-Analysis    
Journal Detail:
Title:  Journal of Zhejiang University. Science. B     Volume:  11     ISSN:  1862-1783     ISO Abbreviation:  J Zhejiang Univ Sci B     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-09-27     Completed Date:  2011-01-21     Revised Date:  2013-07-03    
Medline Journal Info:
Nlm Unique ID:  101236535     Medline TA:  J Zhejiang Univ Sci B     Country:  China    
Other Details:
Languages:  eng     Pagination:  754-61     Citation Subset:  IM    
Department of Cardiology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Balloon, Coronary*
Antineoplastic Agents, Phytogenic / administration & dosage*
Drug-Eluting Stents*
Myocardial Infarction / therapy*
Paclitaxel / administration & dosage*
Randomized Controlled Trials as Topic
Treatment Outcome
Reg. No./Substance:
0/Antineoplastic Agents, Phytogenic; 33069-62-4/Paclitaxel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Derived vascular endothelial cells induced by mucoepidermoid carcinoma cells: 3-dimensional collagen...
Next Document:  FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics.